See more : Sparinvest INDEX USA Small Cap KL (SPIUSSKL.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Gland Pharma Limited (GLAND.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gland Pharma Limited, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- HORAI Co., Ltd. (9679.T) Income Statement Analysis – Financial Results
- Southern Gold Limited (SAU.AX) Income Statement Analysis – Financial Results
- Shanghai General Healthy Information and Technology Co., Ltd. (605186.SS) Income Statement Analysis – Financial Results
- Axis Energy Corporation (AXGC) Income Statement Analysis – Financial Results
- Ovostar Union Public Company Limited (OVO.WA) Income Statement Analysis – Financial Results
Gland Pharma Limited (GLAND.NS)
About Gland Pharma Limited
Gland Pharma Limited engages in the development, manufacture, and marketing of injectable-focused generic liquid parenteral products. The company's primary molecules include heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, as well as others. It offers its products under various therapeutic categories, such as anti-infectives, anesthetics, anti-coagulants and their antidotes, anti-malarial, cardiology, gastro-intestinal, pain management, hormones and related drugs, fertility supplements, Gnrh agonists and antagonists, anti-neoplastic, gynecological, neurological and central nervous system, respiratory, blood related, ophthalmological and otological, pain/analgesics, orthopedics, hematinic, vitamins/minerals/nutrients, and others. The company also provides contract development services. It sells its products primarily under a business to business in the United States, Europe, Canada, Australia, India, and internationally. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited is a subsidiary of Fosun Pharma Industrial Pte. Ltd.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 56.42B | 36.25B | 43.84B | 34.24B | 25.72B | 19.93B | 15.80B | 14.79B |
| Cost of Revenue | 25.54B | 16.85B | 21.09B | 14.92B | 11.02B | 8.57B | 6.61B | 5.82B |
| Gross Profit | 30.88B | 19.39B | 22.75B | 19.32B | 14.70B | 11.36B | 9.19B | 8.97B |
| Gross Profit Ratio | 54.73% | 53.50% | 51.89% | 56.42% | 57.15% | 57.00% | 58.18% | 60.62% |
| Research & Development | 1.77B | 403.77M | 426.56M | 321.99M | 228.75M | 207.17M | 189.12M | 507.55M |
| General & Administrative | 1.32B | 485.32M | 313.62M | 162.70M | 139.51M | 88.63M | 503.72M | 0.00 |
| Selling & Marketing | 374.64M | 270.32M | 409.81M | 366.94M | 170.76M | 138.78M | 99.31M | 0.00 |
| SG&A | 12.88B | 755.64M | 723.43M | 529.64M | 310.27M | 227.41M | 603.03M | 1.61B |
| Other Expenses | 0.00 | 2.40B | 15.99M | 82.77M | 9.78M | 5.76M | 2.82M | 0.00 |
| Operating Expenses | 14.66B | 10.61B | 8.75B | 7.28B | 6.07B | 5.22B | 4.61B | 3.32B |
| Cost & Expenses | 40.20B | 27.47B | 29.84B | 22.20B | 17.09B | 13.79B | 11.22B | 9.14B |
| Interest Income | 1.51B | 1.79B | 1.39B | 859.49M | 514.86M | 433.13M | 271.68M | 128.24M |
| Interest Expense | 262.00M | 74.47M | 34.02M | 29.11M | 62.51M | 26.17M | 32.48M | 0.00 |
| Depreciation & Amortization | 3.45B | 1.47B | 1.10B | 987.80M | 945.87M | 821.20M | 783.68M | 741.47M |
| EBITDA | 15.03B | 12.09B | 17.34B | 14.37B | 10.95B | 7.72B | 5.84B | 6.32B |
| EBITDA Ratio | 26.65% | 34.91% | 39.42% | 41.97% | 41.91% | 39.15% | 36.98% | 42.73% |
| Operating Income | 16.45B | 8.84B | 14.00B | 12.03B | 8.61B | 6.24B | 4.58B | 5.58B |
| Operating Income Ratio | 29.16% | 24.40% | 31.93% | 35.15% | 33.47% | 31.33% | 29.00% | 37.72% |
| Total Other Income/Expenses | -5.13B | -1.02B | 2.18B | -839.40M | -526.58M | -726.47M | -1.32B | 201.39M |
| Income Before Tax | 11.33B | 10.55B | 16.19B | 13.35B | 9.93B | 6.86B | 5.01B | 5.78B |
| Income Before Tax Ratio | 20.07% | 29.10% | 36.92% | 38.99% | 38.61% | 34.43% | 31.74% | 39.08% |
| Income Tax Expense | 3.60B | 2.74B | 4.07B | 3.38B | 2.20B | 2.34B | 1.80B | 1.64B |
| Net Income | 7.72B | 7.81B | 12.12B | 9.97B | 7.73B | 4.52B | 3.21B | 4.14B |
| Net Income Ratio | 13.69% | 21.55% | 27.64% | 29.12% | 30.05% | 22.67% | 20.32% | 27.97% |
| EPS | 46.90 | 47.44 | 73.81 | 63.07 | 49.88 | 27.67 | 19.66 | 26.70 |
| EPS Diluted | 46.89 | 47.43 | 73.64 | 62.99 | 49.88 | 27.67 | 19.66 | 26.70 |
| Weighted Avg Shares Out | 164.70M | 164.64M | 164.15M | 158.08M | 154.95M | 163.28M | 163.28M | 154.95M |
| Weighted Avg Shares Out (Dil) | 164.73M | 164.68M | 164.54M | 158.28M | 154.95M | 163.28M | 163.28M | 154.95M |
Source: https://incomestatements.info
Category: Stock Reports